Literature DB >> 16285013

Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation.

María-Luisa del Rio1, Giovanna Penuelas-Rivas, Raul Dominguez-Perles, Pablo Ramirez, Pascual Parrilla, Jose-Ignacio Rodriguez-Barbosa.   

Abstract

Programmed death-1 (PD-1, CD279) is a molecule expressed on activated T, B and myeloid cells. The role of the interaction of PD-1 ligands (PD-L1 and PD-L2) with PD-1 receptor and the type of signals (costimulatory or inhibitory) that are delivered is a subject of intense debate. Our study has characterized two monoclonal antibodies (mAb) against murine PD-1, termed clone 1H10 and clone 4F10, that recognized different epitopes from that of anti-PD-1, clone J43. We showed that neither of them inhibited anti-CD3-mediated proliferation, but 1H10 mAb induced direct T cell proliferation in the absence of any other stimulus. Moreover, PD-1 engagement with 1H10 mAb costimulated anti-CD3-mediated proliferation and enhanced anti-CD3/CD28 proliferation on both CD4+ and CD8+ T cells in the low range of anti-CD3 concentrations. Anti-PD-1-mediated proliferation induced with 1H10 mAb was also observed in vivo on CD4+ and CD8+ T cells, when CFSE-labeled splenocytes were adoptively transferred to irradiated syngeneic and allogeneic recipients. Overall, our data indicate that PD-1 might not only deliver negative signals to T cells upon interaction through one of its ligands, PD-L1 as reported, but also could costimulate T cells, suggesting a dual potential functional activity of the extracellular domains of this receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16285013     DOI: 10.1002/eji.200535232

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  T cell and APC dynamics in situ control the outcome of vaccination.

Authors:  Kamal M Khanna; David A Blair; Anthony T Vella; Stephen J McSorley; Sandip K Datta; Leo Lefrançois
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 2.  Immunoregulatory role of B7-H1 in chronicity of inflammatory responses.

Authors:  Haidong Dong; Xianming Chen
Journal:  Cell Mol Immunol       Date:  2006-06       Impact factor: 11.530

3.  Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Authors:  Mikayel Mkrtichyan; Yana G Najjar; Estella C Raulfs; Maher Y Abdalla; Raed Samara; Rinat Rotem-Yehudar; Larry Cook; Samir N Khleif
Journal:  Eur J Immunol       Date:  2011-08-17       Impact factor: 5.532

4.  Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction.

Authors:  Maria-Luisa del Rio; Nick D Jones; Leo Buhler; Paula Norris; Yasushi Shintani; Carl F Ware; Jose-Ignacio Rodriguez-Barbosa
Journal:  J Immunol       Date:  2012-04-06       Impact factor: 5.422

5.  Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism.

Authors:  Kenneth D Bishop; John E Harris; John P Mordes; Dale L Greiner; Aldo A Rossini; Michael P Czech; Nancy E Phillips
Journal:  Cell Immunol       Date:  2009-02-23       Impact factor: 4.868

6.  Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques.

Authors:  David A Hokey; F Brad Johnson; Jasmine Smith; Joshua L Weber; Jian Yan; Lauren Hirao; Jean D Boyer; Mark G Lewis; George Makedonas; Michael R Betts; David B Weiner
Journal:  Eur J Immunol       Date:  2008-05       Impact factor: 5.532

7.  Therapeutic blockade of LIGHT interaction with herpesvirus entry mediator and lymphotoxin β receptor attenuates in vivo cytotoxic allogeneic responses.

Authors:  Maria-Luisa del Rio; Carlos Fernandez-Renedo; Stefanie Scheu; Klaus Pfeffer; Yasushi Shintani; Mitchell Kronenberg; Olivier Chaloin; Pascal Schneider; Jose-Ignacio Rodriguez-Barbosa
Journal:  Transplantation       Date:  2014-12-15       Impact factor: 4.939

8.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Authors:  Joseph F Grosso; Cristin C Kelleher; Timothy J Harris; Charles H Maris; Edward L Hipkiss; Angelo De Marzo; Robert Anders; George Netto; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

9.  NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.

Authors:  Foluso O Ademuyiwa; Wiam Bshara; Kristopher Attwood; Carl Morrison; Stephen B Edge; Adam R Karpf; Smith A James; Christine B Ambrosone; Tracey L O'Connor; Ellis G Levine; Anthony Miliotto; Erika Ritter; Gerd Ritter; Sacha Gnjatic; Kunle Odunsi
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

Review 10.  Cancer treatment: the combination of vaccination with other therapies.

Authors:  Mads Hald Andersen; Rikke Baek Sørensen; David Schrama; Inge Marie Svane; Jürgen C Becker; Per Thor Straten
Journal:  Cancer Immunol Immunother       Date:  2008-02-20       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.